antibody

MAb to CD59

MBS312330

0.1 mg

280 USD

monoclonal

mouse

nonconjugated

[MEM-43]

immunoprecipitation, flow cytometry

Antibody

MAb to CD59

[CD59]

[Monoclonal Antibody to Human CD59]

[CD59 glycoprotein preproprotein; CD59 glycoprotein; CD59 glycoprotein; protectin; 1F5 antigen; MEM43 antigen; Ly-6-like protein; OTTHUMP00000232408; OTTHUMP00000232409; OTTHUMP00000232410; OTTHUMP00000232411; OTTHUMP00000232412; OTTHUMP00000232413; OTTHUMP00000232414; OTTHUMP00000232415; OTTHUMP00000232416; OTTHUMP00000232608; OTTHUMP00000232610; T cell-activating protein; human leukocyte antigen MIC11; lymphocytic antigen CD59/MEM43; 20 kDa homologous restriction factor; membrane inhibitor of reactive lysis; membrane attack complex inhibition factor; membrane attack complex (MAC) inhibition factor; surface anitgen recognized by monoclonal antibody 16.3A5; CD59 antigen p18-20 (antigen identified by monoclonal antibodies 16.3A5, EJ16, EJ30, EL32 and G344); CD59 molecule, complement regulatory protein; 1F5 antigen; 20 kDa homologous restriction factor; HRF-20; HRF20; MAC-inhibitory protein; MAC-IP; MEM43 antigen; Membrane attack complex inhibition factor; MACIF; Membrane inhibitor of reactive lysis; MIRL; Protectin]

[CD59; CD59; 1F5; EJ16; EJ30; EL32; G344; MIN1; MIN2; MIN3; MIRL; HRF20; MACIF; MEM43; MIC11; MSK21; 16.3A5; HRF-20; MAC-IP; p18-20; MGC2354; FLJ38134; FLJ92039; MIC11; MIN1; MIN2; MIN3; MSK21]

CD59_HUMAN

m

IgG2a

[MEM-43]

mouse

Human

128

CD59. Reacts with well defined epitope (W40, R-53) on CD59 (Protectin), a 19-25 kDa glycosylphosphatidylinositol (GPI)-anchored glycoprotein expressed on all hematopoietic cells. It is widely present on cells in all tissues.

>95% pure (SDS-PAGE). Protein A chromatography

Purified, Liquid

1mg/ml

Short term store at 2 to 8 degree C. Long term, aliquot and store at -20 degree C. Avoid multiple freeze/thaw cycles.

Flow Cytometry, Immunoprecipitation

Immunogen: Thymocytes and T lymphocytes. Affinity Constant: Not determined

Buffer: PBS, pH 7.4. Preservative: 15mM Sodium azide. Important Note: Centrifuge before opening to ensure complete recovery of vial contents. Warnings: This product contains sodium azide, which has been classified as Xn (Harmful), in European Directive 67/548/EEC in the concentration range of 0.1 - 1.0 %. When disposing of this reagent through lead or copper plumbing, flush with copious volumes of water to prevent azide build-up in drains.

Monoclonal Antibodies to Human CDs

42761474

NP_976074.1

NM_203329.2

P13987

14,177 Da

Arf6 Trafficking Events Pathway (137954); Complement And Coagulation Cascades Pathway (83073); Complement And Coagulation Cascades Pathway (484); Hematopoietic Cell Lineage Pathway (83078); Hematopoietic Cell Lineage Pathway (489)

This gene encodes a cell surface glycoprotein that regulates complement-mediated cell lysis, and it is involved in lymphocyte signal transduction. This protein is a potent inhibitor of the complement membrane attack complex, whereby it binds complement C8 and/or C9 during the assembly of this complex, thereby inhibiting the incorporation of multiple copies of C9 into the complex, which is necessary for osmolytic pore formation. This protein also plays a role in signal transduction pathways in the activation of T cells. Mutations in this gene cause CD59 deficiency, a disease resulting in hemolytic anemia and thrombosis, and which causes cerebral infarction. Multiple alternatively spliced transcript variants, which encode the same protein, have been identified for this gene. [provided by RefSeq]

Function: Potent inhibitor of the complement membrane attack complex (MAC) action. Acts by binding to the C8 and/or C9 complements of the assembling MAC, thereby preventing incorporation of the multiple copies of C9 required for complete formation of the osmolytic pore. This inhibitor appears to be species-specific. Involved in signal transduction for T-cell activation complexed to a protein tyrosine kinase.The soluble form from urine retains its specific complement binding activity, but exhibits greatly reduced ability to inhibit MAC assembly on cell membranes. Subunit structure: Interacts with T-cell surface antigen CD2. Ref.13. Subcellular location: Cell membrane; Lipid-anchor GPI-anchor. Secreted. Note: Soluble form found in a number of tissues. Ref.12 Ref.16 Ref.18 Ref.19 Ref.20. Post-translational modification: N- and O-glycosylated. The N-glycosylation mainly consists of a family of biantennary complex-type structures with and without lactosamine extensions and outer arm fucose residues. Also significant amounts of triantennary complexes (22%). Variable sialylation also present in the Asn-43 oligosaccharide. The predominant O-glycans are mono-sialylated forms of the disaccharide, Gal-beta-1,3GalNAc, and their sites of attachment are probably on Thr-76 and Thr-77. The GPI-anchor of soluble urinary CD59 has no inositol-associated phospholipid, but is composed of seven different GPI-anchor variants of one or more monosaccharide units. Major variants contain sialic acid, mannose and glucosamine Sialic acid linked to an N-acetylhexosamine-galactose arm is present in two variants. Ref.11 Ref.16 Ref.21Glycated. Glycation is found in diabetic subjects, but only at minimal levels in nondiabetic subjects. Glycated CD59 lacks MAC-inhibitory function and confers to vascular complications of diabetes. Involvement in disease: Defects in CD59 are the cause of CD59 deficiency (CD59D) [. MIM:612300]. Ref.25. Sequence similarities: Contains 1 UPAR/Ly6 domain.

0.1 mg

280 USD